Followers | 581 |
Posts | 58320 |
Boards Moderated | 1 |
Alias Born | 09/02/2013 |
Friday, May 26, 2017 3:31:50 PM
Mymetics Corporation Sa
Dr Sylvain Fleury, Chief Scientific Officer, Mymetics Corporation Sa
Dr. Sylvain Fleury has 25 years of experience in infectious diseases, involving pre-clinical & clinical development. He did a Ph.D. in Immunology and Microbiology at the Clinical Research Institute of Montreal (Canada), in collaboration with Genentech (California) and Columbia Hospital (New-York). He did a post-doc at the NIAID/NIH in (Bethesda, USA) from 1993-1996 prior moving in Switzerland at the Beaumont Hospital (CHUV-Lausanne) in 1997. He was involved in various clinical trials, investigating the benefit of antiviral tri-therapies on the disease course and the immune system regeneration, in collaboration with Roche. From 2000 to 2004, Dr. Fleury worked at the Cardiology department (CHUV) for developing gene therapies with adenoviral and lentiviral vectors expressing chemokine antagonists for preventing heart allorejection. Dr. Fleury became the Chief Scientific Officer of MYMETICS Corporation in 2003, developing virosome-based prophylactic vaccines for blocking early events of pathogen transmission and infection (pipeline: HIV, malaria, RSV, influenza), with a high interest in mucosal immunity induction.
Appearances:
?
Day Two 11th October, Human @ 16:30
MACIVIVA – Developing cold chain independent virosomal vaccines
Early Development & Manufacturing
Dr Sylvain Fleury, Chief Scientific Officer, Mymetics Corporation Sa
My post are for entertainment only ...I do not suggest or tell people when to buy or sell..... GLTA STACKER
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM